Pyogenic granuloma in patients treated with selective BRAF inhibitors: another manifestation of paradoxical pathway activation

Henning, Benjamin; Stieger, Pascale; Kamarachev, Jivko; Dummer, Reinhard; Goldinger, Simone M

Abstract: Cutaneous toxicities under therapy with selective BRAF inhibitors such as vemurafenib or encorafenib (LGX818) are frequent, including plantar hyperkeratosis, squamous cell carcinoma, and second primary melanoma. Pyogenic granuloma is a benign, rapidly growing, eruptive hemangioma that often bleeds and ulcerates. Common causes are mechanical trauma and cast immobilization, as well as multiple drugs such as retinoids and antineoplastic agents. However, the development of pyogenic granuloma under treatment with encorafenib (LGX818) has not yet been reported. These three cases might be further examples for paradoxical activation of the mitogen-activated protein kinase pathway. We report three male patients with metastatic BRAFV600E-mutated melanoma who developed pyogenic granulomas 16, 10, and 12 weeks after treatment initiation with the selective BRAF inhibitors vemurafenib or encorafenib (LGX818). Except for one patient receiving retinoids, the clinical history for other frequent causes of pyogenic granuloma was negative. Pyogenic granulomas are not listed in the drugs investigator brochure but seem to be associated with selective BRAF inhibitors and might be a cutaneous phenomenon of paradoxical mitogen-activated protein kinase pathway activation. This correlation has to be confirmed by further observations.

DOI: https://doi.org/10.1097/CMR.0000000000000248

Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-124910
Journal Article
Published Version

Originally published at:
DOI: https://doi.org/10.1097/CMR.0000000000000248
Original Research

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

Lars Hofmann a, Andrea Forschner b, Carmen Loquai c, Simone M. Goldinger d, Lisa Zimmer c, Selma Ugurel e, Maria I. Schmidgen c, Ralf Gutzmer f, Jochen S. Utikal g, Daniela Göppner i, Jessica C. Hassel j, Friedegund Meier k, Julia K. Tietze l, Ioannis Thomas b, Carsten Weßhaupt m, Martin Leverkus n, Renate Wahl n, Ursula Dietrich k, Claus Garbe b, Michael C. Kirchberger a, Thomas Eigentler b, Carola Berking l, Anja Gesierich o, Angela M. Krackhardt p, Dirk Schaden dorf e, Gerold Schuler a, Reinhard Dummer d, Lucie M. Heinzerling a,*

Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Germany

Department of Dermatology, University Hospital Tübingen, Germany

Department of Dermatology, University Hospital Mainz, Germany

Department of Dermatology, University Hospital Zurich, Switzerland

Department of Dermatology, University Hospital Duisburg-Essen, Germany

Department of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, Germany

Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany

Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karls University of Heidelberg, Mannheim, Germany

Department of Dermatology, University Hospital Magdeburg, Germany

Department of Dermatology, University Hospital Heidelberg, Germany

Department of Dermatology, University Hospital Dresden, Germany

Department of Dermatology and Allergology, Ludwig-Maximilian-University (LMU) Munich, Germany

Department of Dermatology, University Hospital Münster, Münster, Germany

Department of Dermatology, University Hospital RWTH Aachen, Germany

Department of Dermatology, University Hospital Würzburg, Germany

III. Medical Department, Technische Universität München (TUM), Munich, Germany

Received 22 February 2016; accepted 25 February 2016
Available online 13 April 2016

* Corresponding author: Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany. Tel.: +49 9131 85 39037; fax: +49 9131 85 36175.
E-mail address: Lucie.Heinzerling@uk-erlangen.de (L.M. Heinzerling).

We like to commemorate Martin Leverkus who was a wonderful colleague, a talented researcher and a good friend.

http://dx.doi.org/10.1016/j.ejca.2016.02.025
0959-8049/© 2016 Elsevier Ltd. All rights reserved.
Abstract Background: Anti-programmed cell death receptor-1 (PD-1) antibodies represent an effective treatment option for metastatic melanoma as well as for other cancer entities. They act via blockade of the PD-1 receptor, an inhibitor of the T-cell effector mechanisms that limit immune responses against tumours. As reported for ipilimumab, the anti-PD-1 antibodies pembrolizumab and nivolumab can induce immune-related adverse events (irAEs). These side-effects affect skin, gastrointestinal tract, liver, endocrine system and other organ systems. Since life-threatening and fatal irAEs have been reported, adequate diagnosis and management are essential.

Methods and findings: In total, 496 patients with metastatic melanoma from 15 skin cancer centers were treated with pembrolizumab or nivolumab; 242 side-effects were described in 138 patients. In 116 of the 138 patients, side-effects affected the skin, gastrointestinal tract, liver, endocrine, and renal system. Rare side-effects included diabetes mellitus, lichen planus, and pancreas insufficiency due to pancreatitis.

Conclusion: Anti-PD1 antibodies can induce a plethora of irAEs. The knowledge of them will allow prompt diagnosis and improve the management resulting in decreased morbidity.

1. Introduction

Nivolumab and pembrolizumab have been shown to enhance pre-existing immune responses including antitumour response by directly blocking programmed cell death receptor-1 (PD-1) which is a checkpoint of the effector stage of the immune system [1,2]. While the response rate of ipilimumab-treated patients is around 10–15% [3,4], response rates of pembrolizumab- and nivolumab-treated patients are 33% [5] and 32% [6], respectively.

Grade 3–4 adverse events (AEs) are observed in 22–24% of ipilimumab-treated patients [7,8], in 5–10% of nivolumab- and pembrolizumab-treated patients [5,6] and in 54–55% of ipilimumab plus nivolumab-treated patients [8,9]. A permanent discontinuation of therapy due to side-effects has been reported in 5% of patients treated with anti-PD-1 antibodies [10]. All checkpoint inhibitors can potentially induce immune-related AEs (irAEs) in any organ system. In contrast to ipilimumab, treatment with anti-PD-1 antibodies is continuous with some studies finishing application after 2 years. Thus, irAEs can occur late after initiation of therapy but possibly also after cessation of therapy. To date, cases of rare life-threatening or even fatal side-effects have been reported after anti-PD-1 antibody therapy like severe skin reactions [11], diabetes mellitus type 1 [12], and rhabdomyolysis [13].

Both nivolumab and pembrolizumab are approved for treatment of metastatic melanoma, nivolumab also for squamous non-small-cell lung cancer (NSCLC) after prior chemotherapy. Since they are also effective in various other tumour entities, they are expected to be employed widely. Therefore, physicians should be aware of potential side-effects. To facilitate prompt diagnosis and adequate management, cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects are summarised. Rare and therapeutically challenging side-effects from 15 cancer centers in Germany and Switzerland are described in detail.

2. Methods

2.1. Ethics statement

This retrospective study was approved by the local institutional review board of the Friedrich-Alexander-University Erlangen-Nuremberg (approval number 17_16Bc). In addition, all clinical protocols were reviewed and approved by the local institutional review boards of each participating center and were performed according to Good Clinical Practice and the Helsinki Declaration.

2.2. Study centers and treatment settings

Fifteen participating study centers in Germany and Switzerland screened patient files for pembrolizumab- and nivolumab-associated irAEs and reported them. AEs were graded according to the National Cancer Institute Common Toxicity Criteria (CTC, version 4.0). If not otherwise stated, pembrolizumab was administered intravenously over 30 min at a dose of 2 mg/kg body weight every 3 weeks and nivolumab over 60 min at a dose of 3 mg/kg body weight every 2 weeks. Based upon the authors’ discretion, additional information was requested for the 15 most compelling and instructive cases of cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects.
3. Results

A total of 496 melanoma patients were treated with nivolumab or pembrolizumab at 15 skin cancer centers; 242 irAEs were reported in 138 patients. In 116 of the 138 patients, side-effects affected skin (43 patients), endocrine system (30 patients), gastrointestinal tract (21 patients), liver (11 patients), pancreas (9 patients), and the renal system (2 patients).

3.1. Skin

Skin reactions are the most common side-effects under treatment with anti-PD-1 or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies and play an important role for patients. Under treatment with ipilimumab, up to 50% of the patients suffer from pruritus and rash with very few serious adverse skin reactions (grade 3–5) [4,14,15]. Patients had skin reactions like rash and pruritus in 28–37% and vitiligo in 9–11% under nivolumab and pembrolizumab [5,16]. Furthermore, rare cutaneous side-effects like exacerbating psoriasis vulgaris [17–20], exfoliative dermatitis [20], and erythema multiforme [20,21] have been documented. Therapy with anti-PD-1 antibodies may also increase radiosensitivity and can thus in combination with radiotherapy induce acute skin reaction [11] similarly reported for B-Raf proto-oncogene, serine/threonine kinase (BRAF) inhibitors [22,23]. Also a case of lichen planus pemphigoides under treatment with pembrolizumab [24] and two cases of an induced bullous pemphigoid [25,26] were reported.

In our analysis, 43 patients (8.7%) presented with dermatological side-effects (Table 1). These included common skin events like pruritus, rash and eczema in 19 patients (3.8%), vitiligo in 13 patients (2.6%), alopecia in 7 patients (1.4%), and lichenoid and cytotoxic skin reactions in 4 patients (0.8%). Psoriasis vulgaris and lichen planus mucosae were reported in two patient each. Sweet’s syndrome, lichen planus, and lichen sclerosus et atrophicus were documented in one patient each. Only three cutaneous AEs—lichenoid skin reaction, lichen ruber mucosae, and Sweet’s syndrome—were graded as severe, i.e. grade 3. All other events were documented as grade 1–2 and could be managed with topical corticosteroids, systemic antihistaminic therapy, or did not require treatment. Only one patient with pruritus received systemic corticosteroid therapy. All grade 3 AEs led to pause of treatment with anti-PD-1 and resolved or improved even after continuation of anti-PD-1. The patient with lichenoid skin reaction received systemic prednisolone (1 mg/kg body weight orally [p.o.]).

3.1.1. Patient 1—Vitiligo of the skin

A 55-year-old male patient with metastatic melanoma stage IV was treated with pembrolizumab. After 44 weeks of treatment, the patient developed a distinctive vitiligo with accentuation of his face and chest (Fig. 1A).

3.1.2. Patient 2—Vitiligo of the hair

After systemic therapy with vemurafenib and ipilimumab, a 53-year-old woman with stage IV metastatic melanoma received pembrolizumab (10 mg/kg body weight intravenous [i.v.]) every 3 weeks. Eighteen weeks after the first cycle with pembrolizumab, the patient developed depigmentation of her eyelashes, eyebrows (Fig. 1B), and her axillary and pubic hair which still persists.

3.1.3. Patient 3—Lichen planus mucosae

An 87-year-old male patient, pretreated with radiation therapy, carboplatin/paclitaxel and ipilimumab, was started on treatment with pembrolizumab. In addition to pneumonitis, vitiligo, and autoimmune hepatitis, the patient developed white pruritic and reticular plaques in his buccal cavity and on his tongue (Fig. 2A) approximately 1 year after initiation of anti-PD-1 treatment. Furthermore, he had a painful erosion on his glans penis (Fig. 2A). Histopathological analysis confirmed the diagnosis of lichen ruber planus mucosae. Direct and indirect immunofluorescence, antinuclear antibody (ANA) titer, and anti-desmoglein-3 and anti-desmoglein-1 antibodies were negative. Topical therapy with triamcinolone acetonide (adhesive ointment) for the buccal mucosa and with methylprednisolone for the balanitis was initiated. In addition, systemic analgesic therapy and local antiseptic therapy were administered. Four weeks later, almost all buccal and genital skin changes had resolved. Pembrolizumab was paused for 3 weeks and the lichen planus mucosae did not recidivate upon continuation of anti-PD1 therapy.

3.1.4. Patient 4—Lichen planus

A 46-year-old patient started treatment with pembrolizumab for metastatic melanoma. After eight cycles, he developed painful and itchy hyperkeratotic papules and nodules at his hands, feet, forearms, and trunk (Fig. 2B). Histopathological analysis revealed lichen planus with hypergranulosus, orthohyperkeratosis, and dense lichenoid infiltrate in the upper corium and some apoptotic keratinocytes (civatte bodies; Fig. 2B). Local treatment with corticosteroids and urea- and salicylic acid-containing ointments as well as systemic therapy with levocetirizine 5 mg per day were started. After a few weeks, the skin lesions improved markedly. Computed tomography (CT) scans revealed regression of metastases. Treatment with pembrolizumab is currently ongoing. Local treatment with corticosteroids and urea- and salicylic acid-containing ointments as well as systemic therapy with levocetirizine 5 mg per day is continued.
<table>
<thead>
<tr>
<th>Type of side-effect</th>
<th>Grade</th>
<th>Anti-PD-1 antibody</th>
<th>Occurrence in week(s) after initiation of anti-PD-1</th>
<th>Treatment of side-effect</th>
<th>Outcome of side-effect</th>
<th>Clinical tumour response to anti-PD-1</th>
<th>Gender (female/male)</th>
<th>Age</th>
<th>Pre-treatments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitiligo</td>
<td>1 n</td>
<td>No treatment</td>
<td>Not resolved PR f 53</td>
<td>No prior treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitiligo (hypopigmentation around naevi)</td>
<td>1 n</td>
<td>No treatment</td>
<td>Not resolved PR m 66</td>
<td>No prior treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitiligo</td>
<td>1 p</td>
<td>No treatment</td>
<td>Not resolved SD f 61</td>
<td>Dacarbazine; ipilimumab; carboplatin/paclitaxel; fotemustine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitiligo</td>
<td>1 p</td>
<td>No treatment</td>
<td>Not resolved PR m 46</td>
<td>Binimetinib; dacarbazine; anti-endosialin-antibody; ipilimumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitiligo</td>
<td>2 p</td>
<td>No treatment</td>
<td>Not resolved PR f 71</td>
<td>Polychemotherapy with hydroxyurea; dacarbazine; Carmustine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitiligo of hair</td>
<td>1 p</td>
<td>No treatment</td>
<td>Not resolved PR f 53</td>
<td>Vemurafenib; ipilimumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lichen planus mucosae</td>
<td>2 n</td>
<td>Topical corticosteroids; topical pimecrolimus; stomatitis mouthwash solution</td>
<td>Improved PR f 65</td>
<td>No prior treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alopecia</td>
<td>1 p</td>
<td>No treatment</td>
<td>Improved SD m 52</td>
<td>Interferon-alpha; Mage-A3 vaccine; paclitaxel; ipilimumab (including 2 reinductions); polychemotherapy; intranodal vaccine; radiotherapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pruritus</td>
<td>1 p</td>
<td>No treatment</td>
<td>Improved PD m 68</td>
<td>Temozolomid; cisplatin; sorafenib; irinotecan; ipilimumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pruritus</td>
<td>1 p</td>
<td>Topical triclosan; topical corticosteroids; topical polidocanol</td>
<td>Not resolved PR f 65</td>
<td>Dacarbazine; ipilimumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pruritus/eczema</td>
<td>1 n</td>
<td>Topical methylprednisolone</td>
<td>Not resolved PR f 34</td>
<td>No prior treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pruritus/xerosis cutis</td>
<td>1 n</td>
<td>No treatment</td>
<td>Not resolved PD m 70</td>
<td>Electrochemotherapy; ipilimumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pruritus/eczema</td>
<td>2 p</td>
<td>Topical corticosteroids; systemic corticosteroids 0.5 mg/kg/d p.o.; pause of pembrolizumab</td>
<td>Improved PR m 54</td>
<td>Dacarbazine; ipilimumab; radiotherapy; carboplatin/paclitaxel</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pruritus</td>
<td>1 p</td>
<td>Topical methylprednisolone</td>
<td>Resolved SD m 79</td>
<td>Radiotherapy; ipilimumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pruritus</td>
<td>2 p</td>
<td>Fexofenadin 180 mg/d; topical corticosteroids</td>
<td>Resolved SD m 66</td>
<td>Interferon-alpha; radiotherapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pruritus</td>
<td>2 p</td>
<td>Clemastine fumarate p.o., hydroxyzine dihydrochloride 25 mg/d p.o.</td>
<td>Not resolved PD m 53</td>
<td>Interferon-alpha; ipilimumab; dacarbazine; carboplatin/paclitaxel; radiotherapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type of side-effect</td>
<td>Grade CTCAE</td>
<td>Anti-PD-1 antibody</td>
<td>Occurrence in week(s) after initiation of anti-PD-1</td>
<td>Treatment of side-effect</td>
<td>Outcome of side-effect</td>
<td>Clinical tumour response to anti-PD-1</td>
<td>Gender (female/male)</td>
<td>Age</td>
<td>Pre-treatments</td>
</tr>
<tr>
<td>---------------------</td>
<td>------------</td>
<td>--------------------</td>
<td>-----------------------------------------------</td>
<td>--------------------------</td>
<td>------------------------</td>
<td>-------------------------------------</td>
<td>---------------------</td>
<td>-----</td>
<td>----------------</td>
</tr>
<tr>
<td>Erysipelas-like skin inflammation around responding cutaneous metastases</td>
<td>2</td>
<td>n</td>
<td>6</td>
<td>No treatment</td>
<td>Ongoing</td>
<td>SD</td>
<td>m</td>
<td>60</td>
<td>Interferon-alpha; interferon pegylated; ipilimumab</td>
</tr>
<tr>
<td>Eczema</td>
<td>1</td>
<td>n</td>
<td>4</td>
<td>Topical corticosteroids</td>
<td>Resolved</td>
<td>PD</td>
<td>m</td>
<td>78</td>
<td>Interferon-alpha</td>
</tr>
<tr>
<td>Pruritus</td>
<td>2</td>
<td>p</td>
<td>1</td>
<td>Topical corticosteroids; topical polidocanol</td>
<td>Resolved</td>
<td>PD</td>
<td>m</td>
<td>59</td>
<td>Radiotherapy; ipilimumab</td>
</tr>
<tr>
<td>Rash</td>
<td>2</td>
<td>p</td>
<td>1</td>
<td>Topical corticosteroids; topical polidocanol</td>
<td>Resolved</td>
<td>PD</td>
<td>m</td>
<td>59</td>
<td>Radiotherapy; ipilimumab</td>
</tr>
<tr>
<td>Hair growth (body)</td>
<td>1</td>
<td>p</td>
<td>26</td>
<td>No treatment</td>
<td>Not resolved</td>
<td>PR</td>
<td>m</td>
<td>55</td>
<td>Interferon-alpha; radiotherapy; dacarbazine; ipilimumab; vemurafenib</td>
</tr>
<tr>
<td>Hyperkeratosis (body)</td>
<td>1</td>
<td>p</td>
<td>26</td>
<td>No treatment</td>
<td>Not resolved</td>
<td>PR</td>
<td>m</td>
<td>55</td>
<td>Interferon-alpha; radiotherapy; dacarbazine; ipilimumab; vemurafenib</td>
</tr>
<tr>
<td>Vitiligo</td>
<td>2</td>
<td>p</td>
<td>44</td>
<td>No treatment</td>
<td>Not resolved</td>
<td>PR</td>
<td>m</td>
<td>55</td>
<td>Interferon-alpha; radiotherapy; dacarbazine; ipilimumab; vemurafenib</td>
</tr>
<tr>
<td>Pruritus/eczema</td>
<td>2</td>
<td>p</td>
<td>1</td>
<td>Topical hydrocortisone; topical mometasone furoate; topical urea</td>
<td>Improved</td>
<td>SD</td>
<td>f</td>
<td>81</td>
<td>Dacarbazine; SIRT; ipilimumab; radiotherapy</td>
</tr>
<tr>
<td>Rash face</td>
<td>2</td>
<td>p</td>
<td>1</td>
<td>Topical hydrocortisone; topical mometasone furoate; topical ketoconazole</td>
<td>Resolved</td>
<td>SD</td>
<td>f</td>
<td>81</td>
<td>Dacarbazine; SIRT; ipilimumab; radiotherapy</td>
</tr>
<tr>
<td>Vitiligo</td>
<td>1</td>
<td>p</td>
<td>1</td>
<td>No treatment</td>
<td>Not resolved</td>
<td>PR</td>
<td>m</td>
<td>69</td>
<td>Radiochemotherapy; carboplatin/paclitaxel; ipilimumab</td>
</tr>
<tr>
<td>Pruritus</td>
<td>1</td>
<td>p</td>
<td>1</td>
<td>Indifferential topical therapy; antihistaminic p.o.</td>
<td>Resolved</td>
<td>PR</td>
<td>m</td>
<td>69</td>
<td>Radiochemotherapy; carboplatin/paclitaxel; ipilimumab</td>
</tr>
<tr>
<td>Pruritus</td>
<td>1</td>
<td>p</td>
<td>12</td>
<td>No treatment</td>
<td>Not resolved</td>
<td>PR</td>
<td>m</td>
<td>64</td>
<td>Radiotherapy; dacarbazine; carboplatin/paclitaxel; ipilimumab</td>
</tr>
<tr>
<td>Pruritus</td>
<td>1</td>
<td>p</td>
<td>27</td>
<td>Indifferential topical therapy</td>
<td>Improved</td>
<td>CR</td>
<td>m</td>
<td>54</td>
<td>Interferon-alpha; DC vaccine; ipilimumab</td>
</tr>
<tr>
<td>Hyperkeratosis (fingers)</td>
<td>2</td>
<td>p</td>
<td>3</td>
<td>No treatment</td>
<td>Not resolved</td>
<td>PD</td>
<td>m</td>
<td>49</td>
<td>Interferon-alpha; radiotherapy; ipilimumab; dabrafenib; dabrafenib/trametinib</td>
</tr>
<tr>
<td>Pruritus</td>
<td>2</td>
<td>p</td>
<td>1</td>
<td>Topical corticosteroids; topical polidocanol</td>
<td>Resolved</td>
<td>SD</td>
<td>m</td>
<td>69</td>
<td>Interferon-alpha; dacarbazine; ipilimumab</td>
</tr>
<tr>
<td>Lichenoid skin reaction</td>
<td>3</td>
<td>p</td>
<td>1</td>
<td>Prednisolone 1 mg/kg/d; pause of pembrolizumab</td>
<td>Resolved</td>
<td>PD</td>
<td>m</td>
<td>79</td>
<td>Ipilimumab</td>
</tr>
<tr>
<td>Vitiligo</td>
<td>1</td>
<td>p</td>
<td>51</td>
<td>No treatment</td>
<td>Not resolved</td>
<td>PR</td>
<td>m</td>
<td>74</td>
<td>Ipilimumab</td>
</tr>
<tr>
<td>Lichenoid skin reaction</td>
<td>1</td>
<td>p</td>
<td>54</td>
<td>No treatment</td>
<td>Resolved</td>
<td>PR</td>
<td>m</td>
<td>74</td>
<td>Ipilimumab</td>
</tr>
<tr>
<td>Condition</td>
<td>No.</td>
<td>Type</td>
<td>Description</td>
<td>Outcome</td>
<td>Score</td>
<td>Therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>-----</td>
<td>------</td>
<td>--------------------------------------------------------------------------------</td>
<td>---------</td>
<td>-------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitiligo</td>
<td>1 p</td>
<td>50</td>
<td>No treatment</td>
<td>Not resolved</td>
<td>PR</td>
<td>m 49 MEK inhibitor/panBRAF-inhibitor; ipilimumab; cisplatin/vindesine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cytotoxic skin reaction</td>
<td>1 p</td>
<td>3</td>
<td>Topical corticosteroids; indifferential topical therapy</td>
<td>Resolved</td>
<td>SD</td>
<td>m 83 Ipilimumab</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rash</td>
<td>1 p</td>
<td>7</td>
<td>Topical corticosteroids</td>
<td>Resolved</td>
<td>PR</td>
<td>m 35 Ipilimumab</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rash</td>
<td>1 p</td>
<td>6</td>
<td>Topical corticosteroids</td>
<td>Resolved</td>
<td>PR</td>
<td>m 68 Ipilimumab</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitiligo</td>
<td>1 p</td>
<td>50</td>
<td>No treatment</td>
<td>Not resolved</td>
<td>PR</td>
<td>m 68 Ipilimumab</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitiligo</td>
<td>1 p</td>
<td>25</td>
<td>No treatment</td>
<td>Not resolved</td>
<td>PR</td>
<td>m 80 Dacarbazine; ipilimumab</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lichenoid skin reaction</td>
<td>1 p</td>
<td>38</td>
<td>Topical corticosteroids</td>
<td>Not resolved</td>
<td>PR</td>
<td>m 80 Dacarbazine; ipilimumab</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitiligo</td>
<td>1 p</td>
<td>3</td>
<td>No treatment</td>
<td>Not resolved</td>
<td>PD</td>
<td>f 57 Ipilimumab</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cold hands</td>
<td>1 n</td>
<td>1</td>
<td>No treatment</td>
<td>Resolved</td>
<td>PR</td>
<td>m 76 Ipilimumab (including reinduction); radiotherapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lichen sclerosus et atrophicus</td>
<td>1 n</td>
<td>68</td>
<td>No treatment</td>
<td>Resolved</td>
<td>PR</td>
<td>m 76 Ipilimumab (including reinduction); radiotherapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alopecia</td>
<td>1 n</td>
<td>75</td>
<td>No treatment</td>
<td>Resolved</td>
<td>PR</td>
<td>f 62 Interferon-alpha</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feverle neutropenia with rash (sweet’s syndrome)</td>
<td>3 n</td>
<td>10</td>
<td>Pause of nivolumab</td>
<td>Resolved</td>
<td>CR</td>
<td>f 70 No prior treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alopecia</td>
<td>1 n</td>
<td>22</td>
<td>No treatment</td>
<td>Not resolved</td>
<td>CR</td>
<td>f 70 No prior treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Penile oedema</td>
<td>1 n</td>
<td>7</td>
<td>No treatment</td>
<td>Not resolved</td>
<td>PR</td>
<td>m 71 No prior treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psoriasis vulgaris</td>
<td>1 n</td>
<td>53</td>
<td>Topical calcipotriol and betamethasone</td>
<td>Not resolved</td>
<td>PR</td>
<td>m 71 No prior treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alopecia</td>
<td>1 n</td>
<td>7</td>
<td>No treatment</td>
<td>Not resolved</td>
<td>SD</td>
<td>f 59 Ipilimumab</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atopic dermatitis (worsening)</td>
<td>1 n</td>
<td>2</td>
<td>Topical moisturising ointment</td>
<td>Not resolved</td>
<td>PD</td>
<td>m 45 Interferon-alpha; ipilimumab; radiotherapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alopecia (loss of eyelashes)</td>
<td>1 p</td>
<td>11</td>
<td>No treatment</td>
<td>Resolved</td>
<td>PR</td>
<td>f 29 Interferon-alpha; dacarbazine; ipilimumab; paclitaxel</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alopecia (loss of eyelashes)</td>
<td>1 p</td>
<td>35</td>
<td>No treatment</td>
<td>Resolved</td>
<td>PR</td>
<td>f 29 Interferon-alpha; dacarbazine; ipilimumab; paclitaxel</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased growth of hair (body)</td>
<td>1 p</td>
<td>19</td>
<td>No treatment</td>
<td>Not resolved</td>
<td>PR</td>
<td>f 29 Interferon-alpha; dacarbazine; ipilimumab; paclitaxel</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lichen planus</td>
<td>2 p</td>
<td>21</td>
<td>Topical corticosteroids and urea- and acetylsalicylic acid-containing ointments; systemic levocetirizine 5 mg/d</td>
<td>Improved</td>
<td>PR</td>
<td>m 45 Interferon-alpha; dacarbazine/darleukin; ipilimumab; carboplatin/ paclitaxel</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psoriasis vulgaris (worsening)</td>
<td>2 p</td>
<td>2</td>
<td>Topical therapy</td>
<td>Improved</td>
<td>SD</td>
<td>m 69 Interferon-alpha; dacarbazine; ipilimumab</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lichen planus mucosae</td>
<td>3 p</td>
<td>49</td>
<td>Topical triamcinolone and methylprednisolone; topical antiseptic therapy; systemic analgesic therapy; pause of pembrolizumab</td>
<td>Improved</td>
<td>PR</td>
<td>m 69 Radiochemotherapy; carboplatin/paclitaxel; ipilimumab</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exanthema (maculated)</td>
<td>2 p</td>
<td>1</td>
<td>Prednisolone 60 mg/d p.o. over 3 d; cetirizine p.o.</td>
<td>Improved</td>
<td>n/a</td>
<td>f 30 Radiotherapy; interferon-alpha; DC vaccine</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: p, pembrolizumab; n, nivolumab; CTCAE, Common Terminology Criteria for Adverse Events; SD, stable disease; PR, partial response; CR, complete response; PD, progressive disease; n/a, not applicable; SIRT, selective internal radiation therapy; DC, dendritic cell; p.o., oral.
3.1.5. Patients 5, 6 and 7—alopecia

Patient 5: A 62-year-old female patient complained about hair loss starting after 35 infusions of nivolumab as first-line treatment of metastatic melanoma. Apart from that, she had tolerated the therapy well. The degree of hair loss varied but a wig or other therapeutic intervention was not needed. Under ongoing anti-PD-1 treatment, the AE resolved after 2 months.

Patient 6: A 70-year-old female patient complained about hair loss starting after eight infusions of nivolumab as first-line treatment of metastatic melanoma. The patient was terrified from the sudden onset of hair loss.

Fig. 1. (A) Vitiligo of the skin: depigmentation of the upper body and head with a bizarre and irregular border under black light in a melanoma patient after 44 weeks under treatment with pembrolizumab. (B) Vitiligo of the hair: eyebrows and eyelashes of a 53-year-old female patient before (a) and 18 weeks after treatment with pembrolizumab (b).
Fig. 2. (A) Lichen planus mucosae: 87-year-old male patient with pruritic, reticular white lines on the tongue (a, b) and an erosion of the glans penis (c) 49 weeks after initiation of pembrolizumab. (B) Lichen planus: on both palms of a 46-year-old pembrolizumab-treated male patient circumscribed, disseminated, and reddened papules with a shiny surface (a). Biopsy of the back of the hand with hyperkeratosis, wedge-shaped acanthosis, subepidermal dense lichenoid infiltrate of small lymphocytes that obscures the dermal–epidermal interface (b).
and chose to wear a wig. The degree of hair loss varied over time and was judged not to be severe. After two-and-a-half months, the AE resolved without interruption of anti-PD-1 treatment.

Patient 7: A 59-year-old female patient received three infusions of nivolumab because of progressive metastatic melanoma after therapy with ipilimumab. She complained about increasing hair loss. The density of her hair was reduced in all areas but mainly in a circle at the parietal region. Signs of hair loss alternate with hair growth at the parietal region and are ongoing, but not severe.

3.1.6. Patient 8—Psoriasis vulgaris
After 53 weeks of treatment with nivolumab, a 71-year-old male patient developed erythema and scales on his face. He had no history of psoriasis or atopic dermatitis. Topical treatment with hydrocortisone gel, followed by metronidazole under the suspected diagnosis of corticosteroid-induced dermatitis or rosacea was started. Contact allergy was ruled out by epicutaneous testing. Histology showed a subacute eczema with acanthokeratosis, parahyperkeratosis and spongiosis. The lesions slowly spread and psoriasis was diagnosed presenting with patches of thick, red, and scaly skin on the whole body (including elbows, knees, groins and genital). Under topical therapy including vitamin D analogues in combination with corticosteroids, the skin lesions improved and after cessation of nivolumab, psoriasis slowly resolved.

3.2. Gastrointestinal tract
Gastrointestinal irAEs are common under a treatment with checkpoint inhibitors. Ipilimumab-induced diarrhoea and colitis have been described in 32.8% and abdominal pain in 15.3% with grade 3–4 AEs in approximately 5% [3,27]. Patients under treatment with anti-PD-1 antibodies showed gastrointestinal AEs like diarrhoea in 6.0–16.0% [10,28,29] with grade 3–4 AEs in up to 2.2% [9,10,29,30]. Compared to ipilimumab, the incidence and severity of anti-PD-1 antibody-induced gastrointestinal AEs are much lower [27]. Nevertheless, intestinal perforations under anti-PD-1 treatment have been reported. An elevated calprotectin concentration in the feces before initiation of anti-CTLA-4 antibody therapy or a rapid increasing concentration under treatment seems to correlate with more severe autoimmune-related colitis [31]. As reported for ipilimumab to avoid mucosal biopsies, a non-invasive method for diagnosing checkpoint inhibitor-induced colitis in vivo is confocal laser endomicroscopy [32].

In this study, 21 patients (4.2%) were reported with gastrointestinal AEs (Table 2) including diarrhoea (10 patients), colitis (2 patients), abdominal pain (4 patients), coprostasis (3 patients), xerostomia (3 patients), and oesophagitis (1 patient). The majority of gastrointestinal events were mild and only four grade 3 AEs (diarrhoea) were reported. In persisting grade 2 and grade 3 AEs, checkpoint inhibitor treatment was interrupted and prednisolone (1.0–2.0 mg/kg body weight p.o. or i.v.) administered. Two of the patients suffering from grade 3 diarrhoea received treatment with infliximab (5 mg/kg body weight i.v.). All gastrointestinal events resolved or were ongoing but improving.

3.3. Liver
Hepatitis is another side-effect that can be induced by checkpoint inhibitors. It may be even fatal [3]. Commonly, hepatitis presents with an asymptomatic increase of aspartate transaminase, alanine transaminase and total bilirubin. Sometimes fatigue and fever are associated and radiologic signs of a checkpoint inhibitor-induced hepatitis include hepatomegaly, periportal lymphadenopathy and periporal oedema [33]. Elevated transaminases are reported in <10% in ipilimumab-treated patients [3,27,34] and in 3.7–10.0% anti-PD-1 antibody-treated patients [16,35]. Also a cytomegalovirus (CMV)-induced hepatitis after treatment with ipilimumab has been reported [36]. However, 20% of patients treated for advanced hepatocellular carcinoma showed an increase in transaminases due to treatment with nivolumab [37].

In this study, 11 patients (2.2%) developed hepatitis under treatment with pembrolizumab or nivolumab (Table 3). All events were grade 3–4 and were subsequently treated with prednisolone or methylprednisolone 2 mg/kg body weight p.o. or i.v. while checkpoint inhibitors were interrupted or stopped. Three patients also required treatment with mycophenolate mofetil (500 mg or 1.0 g twice a day [BID] p.o.). Two events improved but were ongoing, all other hepatic AEs resolved.

3.3.1. Patient 9—Hepatitis
After progressive disease under subsequent therapy with vemurafenib and ipilimumab, a 53-year-old female patient with stage IV metastatic melanoma received pembrolizumab (10 mg/kg body weight i.v.) every 3 weeks. Three weeks after the first infusion, the patient presented in a reduced general condition with massive increase of liver transaminases and painful red eyes with photophobia diagnosed as grade 3 iritis. Anti-PD-1 treatment was stopped. Liver biopsy revealed periportal and lobular hepatitis infiltrated with eosinophils and some other inflammatory cells (Fig. 3A). Since systemic steroids (prednisolone 2 mg/kg body weight i.v.) induced only a slight improvement in liver transaminases, mycophenolate mofetil 1 g p.o. BID was added. Hepatic transaminases responded within 24 h and normalised 1 month from the start of mycophenolate without relapse. Iritis was treated with mydriatic agents and dexamethasone eye drops and resolved completely after 4 weeks.
<table>
<thead>
<tr>
<th>Type of side-effect</th>
<th>Grade</th>
<th>Anti-PD-1 antibody</th>
<th>Occurrence in week(s) after initiation of anti-PD-1</th>
<th>Treatment of side-effect</th>
<th>Outcome of side-effect</th>
<th>Clinical tumour response to anti-PD-1</th>
<th>Gender (female/male)</th>
<th>Age</th>
<th>Pre-treatments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhoea</td>
<td>3</td>
<td>p</td>
<td>24</td>
<td>Prednisolone 2 mg/kg/d i.v.; pause of pembrolizumab</td>
<td>Resolved</td>
<td>PR</td>
<td>f</td>
<td>71</td>
<td>Polychemotherapy with hydroxyurea; dacarbazine; Carmustine</td>
</tr>
<tr>
<td>Lymphocytic colitis</td>
<td>3</td>
<td>p</td>
<td>49</td>
<td>Prednisolone 2 mg/kg/d i.v.; infliximab 5 mg/kg i.v.; pause of pembrolizumab</td>
<td>Resolved</td>
<td>SD</td>
<td>f</td>
<td>68</td>
<td>Isolated limb perfusion; dacarbazine; fotemustine; vemurafenib; ipilimumab; temozolomide; electrochemotherapy with bleomycin</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>2</td>
<td>p</td>
<td>2</td>
<td>Prednisolone 2 mg/kg/d i.v.</td>
<td>Resolved</td>
<td>PD</td>
<td>f</td>
<td>50</td>
<td>No prior treatment</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>3</td>
<td>p</td>
<td>23</td>
<td>Systemic saccharomyces boulardii; loperamide p.o.; palliative analgesic therapy</td>
<td>Resolved</td>
<td>PD</td>
<td>f</td>
<td>40</td>
<td>Interferon-alpha; vemurafenib; ipilimumab; radiotherapy</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>1</td>
<td>p</td>
<td>4</td>
<td>No treatment</td>
<td>Not resolved</td>
<td>PD</td>
<td>f</td>
<td>44</td>
<td>Interferon-alpha; dabrafenib; ipilimumab; vemurafenib; radiotherapy</td>
</tr>
<tr>
<td>Colitis</td>
<td>2</td>
<td>p</td>
<td>5</td>
<td>Stop of pembrolizumab; loperamide; initial prednisolone 140 mg/d, tapering</td>
<td>Resolved</td>
<td>SD</td>
<td>m</td>
<td>66</td>
<td>Interferon-alpha; radiotherapy</td>
</tr>
<tr>
<td>Xerostomia</td>
<td>1</td>
<td>p</td>
<td>21</td>
<td>Saliva spray</td>
<td>Resolved</td>
<td>PR</td>
<td>m</td>
<td>78</td>
<td>No prior treatment</td>
</tr>
<tr>
<td>Pain abdomen</td>
<td>1</td>
<td>p</td>
<td>6</td>
<td>No treatment</td>
<td>Resolved</td>
<td>PD</td>
<td>m</td>
<td>67</td>
<td>Interferon-alpha; dacarbazine; vaccine; radiotherapy; carboplatin/paclitaxel</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>1</td>
<td>p</td>
<td>1, 4</td>
<td>No treatment</td>
<td>Resolved</td>
<td>PD</td>
<td>m</td>
<td>45</td>
<td>Interferon-alpha; dacarbazine; carboplatin/paclitaxel; carboplatin; vaccine; radiotherapy; ipilimumab (including reinduction)</td>
</tr>
<tr>
<td>Pain abdomen</td>
<td>1</td>
<td>p</td>
<td>1, 4</td>
<td>No treatment</td>
<td>Resolved</td>
<td>PD</td>
<td>m</td>
<td>45</td>
<td>Interferon-alpha; dacarbazine; carboplatin/paclitaxel; carboplatin; vaccine; radiotherapy; ipilimumab (including reinduction)</td>
</tr>
<tr>
<td>Pain abdomen</td>
<td>1</td>
<td>p</td>
<td>15</td>
<td>Fluid replacement p.o.; warm wet pack</td>
<td>Resolved</td>
<td>PD</td>
<td>m</td>
<td>52</td>
<td>Radiotherapy; carboplatin/paclitaxel; HFTT; ipilimumab</td>
</tr>
<tr>
<td>Coprostasis</td>
<td>2</td>
<td>p</td>
<td>1</td>
<td>Dexamethasone p.o.</td>
<td>Resolved</td>
<td>PR</td>
<td>m</td>
<td>55</td>
<td>Interferon-alpha; radiotherapy; dacarbazine; vemurafenib</td>
</tr>
<tr>
<td>Pain abdomen</td>
<td>1</td>
<td>p</td>
<td>1, 28</td>
<td>No treatment</td>
<td>Resolved</td>
<td>PR</td>
<td>m</td>
<td>64</td>
<td>Radiotherapy; dacarbazine; carboplatin/paclitaxel; ipilimumab</td>
</tr>
<tr>
<td>Oesophagitis</td>
<td>2</td>
<td>p</td>
<td>24</td>
<td>Pantoprazole p.o.</td>
<td>Resolved</td>
<td>PR</td>
<td>m</td>
<td>64</td>
<td>Radiotherapy; dacarbazine; carboplatin/paclitaxel; ipilimumab</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>3</td>
<td>p</td>
<td>15</td>
<td>First line: prednisolone 80 mg/d p.o.; second line: pause of pembrolizumab; infliximab 5 mg/kg i.v.</td>
<td>Improved</td>
<td>PR</td>
<td>m</td>
<td>68</td>
<td>Radiotherapy; dacarbazine; dabrafenib; dabrafenib/trametinib; carboplatin/ paclitaxel; ipilimumab</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>2</td>
<td>n</td>
<td>7</td>
<td>Pause of nivolumab; loperamide p.o.</td>
<td>Resolved</td>
<td>PD</td>
<td>f</td>
<td>68</td>
<td>No prior treatment</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>2</td>
<td>n</td>
<td>8</td>
<td>Loperamide p.o.; probiotic bacteria p.o.</td>
<td>Not resolved</td>
<td>PD</td>
<td>f</td>
<td>36</td>
<td>Radiotherapy; ipilimumab; dacarbazine</td>
</tr>
<tr>
<td>Xerostomia</td>
<td>1</td>
<td>n</td>
<td>10</td>
<td>No treatment</td>
<td>Not resolved</td>
<td>PR</td>
<td>m</td>
<td>76</td>
<td>Ipilimumab (including reinduction); radiotherapy</td>
</tr>
<tr>
<td>Coprostasis</td>
<td>1</td>
<td>n</td>
<td>6</td>
<td>Polyethylene glycol p.o. as needed</td>
<td>Resolved</td>
<td>PR</td>
<td>m</td>
<td>71</td>
<td>No prior treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(continued on next page)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
3.4. Pancreas

Under treatment with anti-CTLA-4 antibodies and anti-PD-1 antibodies grade 3–4 CTCAE elevated levels of serum amylase and lipase were reported in <1–2% [6,20,21,38]. Most of these events were asymptomatic and required no immunosuppressive therapy [39]. Interestingly, some authors do not recommend routine assessment of pancreatic enzymes [14]. In this analysis, nine patients developed pancreatitis (1.8%) of grade 2–4 under treatment with nivolumab or pembrolizumab (Table 4). All patients were treated with systemic corticosteroids ((methyl)prednisolone 1.0–2.0 mg/kg body weight) and treatment was interrupted in four patients. Two patients (grade 4 AEs) additionally required treatment with mycophenolate mofetil. Almost all events resolved with one patient still suffering from pancreas insufficiency.

### 3.4.1. Patient 10—Pancreatitis with pancreas insufficiency

A 65-year-old male patient suffered from stage IV melanoma with hepatic and splenic metastases. After progressive disease under systemic treatment with a mitogen-activated protein kinase (MEK) inhibitor and ipilimumab, anti-PD-1 therapy with pembrolizumab was started. Eleven weeks after initiation, the patient suffered from lack of appetite and pain of his feet. One week later, the patient complained about increasing anorexia, nausea after eating, and an aversion against meat and weight loss. Laboratory findings showed an increased lipase (760 U/l, normal 13–60 U/l) and amylase (378 U/l, <110 U/l).

Abdominal CT revealed a reduced lobulation, tissue swelling, and reduced tissue contrast enhancement of the pancreatic body and tail consistent with a pancreatitis (Fig. 3B). Systemic therapy with prednisolone (100 mg/d i.v.) was initiated, and after 3 d of treatment pancreas enzymes decreased (lipase 760 to 62 U/l and amylase 378 to 99 U/l). Corticosteroid therapy was changed to oral treatment (prednisolone 1 mg/kg body weight) and tapered. The following 5 months an increase of pancreatic enzymes was seen intermittently and led to consecutive enhanced corticosteroid therapy. The first staging 4 months after start of anti-PD-1 therapy showed a mixed tumour response with regressive hepatic but progressive splenic metastases. Eight months after start and nearly 2 months after end of treatment with anti-PD-1, the patient complained about irregular stools with diarrhoea, decolouration of faeces, and absent weight gain despite good appetite. Now pancreatic enzymes were decreased (lipase 7 U/l, normal 13–60 U/l and amylase 46 U/l, normal <110 U/l) and scatoscopy showed a decreased level of elastase (<15 μg/g feces, normal >200 μg/g feces). A pancreas insufficiency was diagnosed and enzymes replaced orally with pancreatic enzyme capsules.

Commonly, asymptomatic increases of pancreatic enzymes have been described so that routine assessment was not recommended [14]. However, this case leading

<table>
<thead>
<tr>
<th>Type of side-effect</th>
<th>Grade</th>
<th>CTCAE</th>
<th>Anti-PD-1 antibody</th>
<th>Occurrence in week(s) after initiation of anti-PD-1; Treatment of side-effect</th>
<th>Outcome of side-effect</th>
<th>Clinical tumour response to anti-PD-1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhoea</td>
<td>1</td>
<td>n</td>
<td>19</td>
<td>Pause of nivolumab</td>
<td>Resolved</td>
<td>SD</td>
</tr>
<tr>
<td>Xerostomia/dry nose</td>
<td>1</td>
<td>n</td>
<td>6</td>
<td>Topical therapy</td>
<td>Not resolved</td>
<td>PR</td>
</tr>
<tr>
<td>Coprostasis</td>
<td>1</td>
<td>n</td>
<td>5</td>
<td>Polyethylene glycol p.o.</td>
<td>Not resolved</td>
<td>PD</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>1</td>
<td>p</td>
<td>3</td>
<td>Metronidazole; butylscopolaminium-bromide; saccharomyces cerevisiae; fluid replacement</td>
<td>Resolved</td>
<td>PR</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>1</td>
<td>p</td>
<td>3</td>
<td>Metronidazole; butylscopolaminium-bromide; saccharomyces cerevisiae; fluid replacement</td>
<td>Resolved</td>
<td>PR</td>
</tr>
<tr>
<td>Xerostomia/dry nose</td>
<td>1</td>
<td>n</td>
<td>6</td>
<td>Topical therapy</td>
<td>Not resolved</td>
<td>PR</td>
</tr>
<tr>
<td>Coprostasis</td>
<td>1</td>
<td>p</td>
<td>3</td>
<td>Metronidazole; butylscopolaminium-bromide; saccharomyces cerevisiae; fluid replacement</td>
<td>Resolved</td>
<td>PR</td>
</tr>
</tbody>
</table>

Abbreviations: p, pembrolizumab; n, nivolumab; CTCAE, Common Terminology Criteria for Adverse Events; SD, stable disease; PR, partial response; PD, progressive disease; HFTT, high-frequency thermotherapy; p.o., Oral; i.v., intravenous.
Table 3
Hepatic side-effects of anti-PD1 therapy.

<table>
<thead>
<tr>
<th>Type of side-effect</th>
<th>Grade</th>
<th>Anti-PD-1 antibody</th>
<th>Occurrence in week(s) after initiation of anti-PD-1</th>
<th>Treatment of side-effect</th>
<th>Outcome of side-effect</th>
<th>Clinical tumour response to anti-PD-1</th>
<th>Gender (female/male)</th>
<th>Age</th>
<th>Pre-treatments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis</td>
<td>3</td>
<td>p</td>
<td>3</td>
<td>Prednisolone 2 mg/kg/d i.v.; mycophenolate mofetil 2×1 g/d; stop of pembrolizumab</td>
<td>Resolved</td>
<td>PR</td>
<td>f</td>
<td>53</td>
<td>Vemurafenib; ipilimumab</td>
</tr>
<tr>
<td>Hepatitis</td>
<td>3</td>
<td>p</td>
<td>1</td>
<td>Stop of pembrolizumab; initial prednisolone 2 mg/kg/d, then: prednisolone 1 g/d i.v.</td>
<td>Resolved</td>
<td>PD</td>
<td>f</td>
<td>46</td>
<td>Interferon-alpha; ipilimumab; electrochemotherapy with bleomycin; interleukin-2 intralesional</td>
</tr>
<tr>
<td>Hepatitis</td>
<td>3</td>
<td>p</td>
<td>4</td>
<td>Pause of pembrolizumab; prednisolone 1 mg/kg/d p.o.</td>
<td>Resolved</td>
<td>PR</td>
<td>m</td>
<td>69</td>
<td>Radiochemotherapy; carboplatin/paclitaxel; ipilimumab</td>
</tr>
<tr>
<td>Hepatitis</td>
<td>3</td>
<td>n</td>
<td>4</td>
<td>Prednisolone 1 mg/kg/d</td>
<td>Resolved</td>
<td>PR</td>
<td>m</td>
<td>53</td>
<td>No prior treatment</td>
</tr>
<tr>
<td>Hepatitis</td>
<td>3</td>
<td>p</td>
<td>3</td>
<td>Prednisolone 2 mg/kg/d</td>
<td>Resolved</td>
<td>PD</td>
<td>f</td>
<td>48</td>
<td>Ipilimumab</td>
</tr>
<tr>
<td>Hepatitis</td>
<td>4</td>
<td>p</td>
<td>3</td>
<td>Stop of pembrolizumab; prednisolone 100 mg/d i.v. 3 d; prednisolone 500 mg/d i.v. 3 d; prednisolone 250 mg/d i.v. 7 d; mycophenolate mofetil 500 mg 2×/d and prednisolone 50 mg/d p.o. 14 d</td>
<td>Resolved</td>
<td>PD</td>
<td>f</td>
<td>35</td>
<td>Ipilimumab</td>
</tr>
<tr>
<td>Hepatitis</td>
<td>4</td>
<td>n</td>
<td>2</td>
<td>Methylprednisolone 2 mg/kg/d; stop of nivolumab</td>
<td>Improved</td>
<td>PR</td>
<td>m</td>
<td>76</td>
<td>Ipilimumab; radiotherapy</td>
</tr>
<tr>
<td>Hepatitis</td>
<td>3</td>
<td>p</td>
<td>4</td>
<td>Pause of pembrolizumab; prednisolone initial 50 mg/d</td>
<td>Resolved</td>
<td>PD</td>
<td>f</td>
<td>75</td>
<td>Dacarbazine; ipilimumab; radiotherapy</td>
</tr>
<tr>
<td>Hepatitis</td>
<td>3</td>
<td>p</td>
<td>2</td>
<td>Pause of pembrolizumab; methylprednisolone 1 mg/kg/d i.v., then p.o. and tapering to prednisolone 5 mg/d</td>
<td>Resolved</td>
<td>PR</td>
<td>f</td>
<td>56</td>
<td>Interferon-alpha; ipilimumab</td>
</tr>
<tr>
<td>Hepatitis</td>
<td>3</td>
<td>p</td>
<td>18</td>
<td>Stop of pembrolizumab; methylprednisolone 2 mg/kg/d; mycophenolate mofetil 500 mg 2×/d; prednisolone p.o., tapering</td>
<td>Resolved</td>
<td>CR</td>
<td>m</td>
<td>72</td>
<td>Interferon-alpha; ipilimumab</td>
</tr>
<tr>
<td>Hepatitis</td>
<td>3</td>
<td>p</td>
<td>1</td>
<td>Prednisolone 2 mg/kg/d p.o.; stop of pembrolizumab</td>
<td>Improved</td>
<td>n/a</td>
<td>m</td>
<td>55</td>
<td>Interferon-alpha; radiotherapy; ipilimumab</td>
</tr>
</tbody>
</table>

Abbreviations: p, pembrolizumab; n, nivolumab; CTCAE, Common Terminology Criteria for Adverse Events; PR, partial response; CR, complete response; PD, progressive disease; n/a, not applicable; p.o., oral; i.v., intravenous.
to pancreas insufficiency indicates that assessing these values is important.

3.5. Endocrine system

IrAEs of the endocrine system are well known from ipilimumab. Common endocrinopathies under anti-CTLA-4 include hyperthyroidism, hypothyroidism (1.5%), hypophysitis (1.8%), and adrenal insufficiency (1.5%) [3,40]. Under treatment with anti-PD-1 antibodies, incidence of hypothyroidism of any grade is approximately 8% [39] and of hyperthyroidism approximately 1–5% [5,20,21].

Endocrine disorders may be difficult to diagnose since symptoms of hypophysitis for instance can be unspecific with fatigue, headache, dizziness, vision changes, sweating, and constipation. Diagnosis is based on hormone work-up and magnetic resonance imaging (MRI) scans which might reveal enlargement of the pituitary gland [41]. Laboratory work-up includes electrolytes, thyroidea-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), cortisol, luteinising hormone, follicle-stimulating hormone, circulating cortisol, testosterone, and insulin-like growth factor-1. Upon diagnosis, prompt treatment with hormones, electrolytes, and/or fluid replacement as required are indicated.

In our analysis, 30 patients (6.0%) developed endocrine disorders (Table 5). Approximately 25% of the events were grade 3–4. Hypothyroidism was reported in 9 patients (1.8%) and hyperthyroidism including thyroiditis in 11 patients (2.2%). Four patients (0.8%) developed hypophysitis and two patients adrenal insufficiency. Furthermore, Hashimoto’s disease was documented in two cases. Four patients (0.8%) developed diabetes mellitus under treatment with nivolumab or pembrolizumab. In all cases, insulin replacement, in one case an insulin perfusor, had to be initiated and maintained. Initial symptoms included increased thirst,
vomiting, and ketoacidosis with increased glucose levels similar to the case of a fulminant diabetes type 1 reported in the literature [12].

3.5.1. Patient 11—Hypophysitis
A 52-year-old male patient, treated with ipilimumab (1 mg/kg body weight i.v.) combined with pembrolizumab (2 mg/kg body weight i.v.) as first-line treatment complained about general weakness, fatigue, lack of appetite, pressure in his ears, and shivering 17 weeks after initiation of treatment. A few days later, he also suffered from less saliva. Endocrine blood tests showed decreased fasting-free cortisol (0 ng/ml, normal 67–226 ng/ml) and adrenocorticotropic hormone (<5.0 pg/ml, normal 5–50 pg/ml), decreased testosterone (3.28 ng/ml, normal 3.5–9 ng/ml), increased interstitial cell-stimulating hormone (8.88 U/l, normal 0.7–6 U/l), increased TSH (6.78 μE/ml, normal 0.4–4.0 μE/ml), increased thyroglobulin (13.10 ng/ml, normal <1.0 ng/ml), and increased prolactin (281.1 mlU/l, normal 55.93–278.18 mlU/l). A systemic corticosteroid treatment with hydrocortisone 10 mg (2–1.5–0) and thyroxine orally was initiated. MRI of the hypophysitis showed a precise extension of the posterior pituitary and contrast medium uptake of the pituitary stalk. After initiation of systemic corticosteroids replacement, the general state of the patient improved.

3.5.2. Patients 12, 13 and 14—Diabetes mellitus type 3
Patient 12: A 70-year-old female patient with no history of diabetes and normal body mass index (20.6) sought medical advice after four treatments of first-line therapy with nivolumab because of increased thirst and circulatory problems. She was admitted because of high blood sugar levels and insulin therapy was started. A new-onset insulin-dependent diabetes type 3 accompanied by a hyperthyreosis was diagnosed. The glutamic acid decarboxylase (GAD) and the islet antigen-2 (IA2) antibodies were negative, and c-peptide was low (<16 pmol/l, normal 140–830 pmol/l). The cause of the sudden onset of the diabetes was considered to be an autoimmune reaction triggered by nivolumab. An MRI scan revealed regression of melanoma and the therapy with nivolumab was continued to maintain the good tumour response that is still present as well as the insulin-dependent diabetes.

Patient 13: A 78-year-old female patient with known diabetes mellitus type 2, which was well controlled with lifestyle changes (diet, physical activity) and without the need for medication, was started on treatment with nivolumab because of progressive metastatic melanoma after therapy with ipilimumab. Metformin was recommended right before initiation of nivolumab. After two infusions of nivolumab, the patient presented with vomiting, diarrhoea, and ketoacidosis. She was promptly admitted and symptomatic treatment as well as an insulin
perfusor was started. In the course of the hospitalisation, the patient developed ketoacidosis again and was transferred to the intensive care unit. The GAD antibodies were positive, the c-peptide low, and the IA2 antibodies were negative. Sudden pancreatic beta cell failure due to an autoimmune reaction induced by the anti-PD-1 antibodies was diagnosed. The newly diagnosed type 3 diabetes mellitus is currently under control and requires insulin therapy.

Patient 14: A 58-year-old female patient with no history of diabetes mellitus had progressive metastatic melanoma after therapy with ipilimumab. At presentation for second cycle of pembrolizumab, she complained about increased thirst and a persistent urge to urinate that had started the day before. A new- and sudden-onset insulin-dependent diabetes mellitus type 3 was diagnosed with low c-peptide, positive GAD II antibodies and IA2 antibodies at the upper limit of normal. An insulin therapy was initiated and after stabilisation of the blood glucose levels the second infusion of pembrolizumab was administered. The patient continues with the eighth infusion of pembrolizumab with stable findings of metastatic disease.

3.6. Renal system

IrAEs affecting the renal system are rare under treatment with anti-CTLA-4 [42] with anecdotic cases of nephritis [43], acute granulomatous interstitial nephritis [43], renal failure with atypical pneumonia, vision loss, and hearing loss [44] and lupus nephritis [45]. Similarly, anti-PD-1 antibodies only rarely induce AEs affecting the renal system with renal failure/nephritis reported in up to 1% of pembrolizumab- or nivolumab-treated patients [5,16,46]. Usually, pause of treatment and administration of corticosteroids (0.5–2.0 mg/kg body weight p.o. or i.v.) usually result in marked improvement [42,47]. In this study, three cases of renal failure/nephritis were documented in two patients (0.4%, Table 6). Both patients responded well to corticosteroid treatment (1.0 mg/kg body weight p.o. and i.v.) and i.v. substitution of electrolytes. Because of ongoing elevated creatinine, in one case a supportive adjuvant application of i.v. fluid before treatment was necessary.

3.6.1. Patient 15—(Interstitial) Nephritis

A 52-year-old male patient with progressive melanoma after therapy with ipilimumab received the third infusion of nivolumab. In the laboratory tests, a grade 2 increase in creatinine was detected. The findings in the urine test were compatible with an interstitial nephritis and prednisolone 100 mg i.v. was started. In addition, the patient received i.v. fluids and the potentially nephrotoxic drugs, i.e. enalapril, indapamide, glimepiride, and dapagliflozin were stopped. Treatment with nivolumab was withheld. After a quick improvement to grade 1 after 3 d, the therapy with corticosteroids was stopped. After 12 d, the AE was resolved and nivolumab therapy was restarted. On the day of admission, creatinine slightly increased again and, therefore, 500 ml of 0.9% sodium chloride were administered right after the administration of nivolumab. Additional fluids were given before all following infusions. Creatinine increased again and has varied in the course of the treatment but not higher than grade 1. After discontinuation of nivolumab treatment because of progressive disease and the start of dexamethasone therapy because of progression of brain metastases with surrounding oedema, creatinine completely normalised.

4. Discussion

In this study, 496 patient records of 15 skin cancer centers were screened for anti-PD-1 AEs and 242 interesting, rare or unexpected, side-effects induced by nivolumab or pembrolizumab were documented in 138 patients (27.8%). Cutaneous, gastrointestinal, hepatic, endocrine, and renal AEs occurred in 116 of the 138 patients and were summarised: Some events are reported for the first time like lichen planus and pancreas insufficiency after pancreatitis. Furthermore, details of rare side-effects like diabetes mellitus type 3 are reported in 4 patients.

Monitoring of patients for side-effects including laboratory findings before, during, and after anti-PD-1 therapy is essential. In accordance with the literature [39], cutaneous AEs under anti-PD-1 treatment are usually mild and well controlled by symptomatic therapy. Most commonly, rashes and vitiligo have been reported. Vitiligo did not require treatment and was associated with a high disease control rate of 92% (12 of 13 patients). This is in accordance with the literature with a disease control rate of 88% (15 in 17 patients) [48]. However, also severe grade 3 lichenoid skin lesions occurred. Interestingly, Goldinger et al. [49] observed in 22% of PD-1-treated patients inflammatory skin lesions ranging from mild maculopapular rashes, typically associated with scaling, and/or lichenoid lesions to very severe Stevens–Johnson syndrome-like skin lesions. Gene expression profiling pathogenically classified all investigated cases as toxic epidermal necrolysis-like reactions. Clinical and histological features of the lesions resembled the findings reported in mice with disrupted PD-1 gene [50]. Overall, most reported AEs in this study were mild with grade 1–2. In this study 24% of AEs were severe (grade 3–4) and three AEs were fatal due to pneumonia and ventricular arrhythmia.

In summary, anti-PD-1 antibodies can affect any organ system and, thus, all symptoms have to be considered as potentially anti-PD-1 associated. Patients have to be accurately informed and instructed to report any symptom. Just as importantly medical staff has to
Table 5
Endocrine side-effects of anti-PD1 therapy.

<table>
<thead>
<tr>
<th>Type of side-effect</th>
<th>Grade</th>
<th>Anti-PD-1 antibody</th>
<th>Occurrence in week(s) after initiation of anti-PD-1</th>
<th>Treatment of side-effect</th>
<th>Outcome of side-effect</th>
<th>Clinical tumour response to anti-PD-1</th>
<th>Gender (female/male)</th>
<th>Age</th>
<th>Pre-treatments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes mellitus type 3</td>
<td>3</td>
<td>n</td>
<td>6</td>
<td>First line: insulin perfusor; second line: protaphane/actrapid pen s.c.; pause of nivolumab</td>
<td>Not resolved</td>
<td>PD</td>
<td>m</td>
<td>40</td>
<td>Dacarbazine; polychemotherapy; ipilimumab</td>
</tr>
<tr>
<td>Hashimoto’s thyroiditis, hypothyroidism</td>
<td>2</td>
<td>n</td>
<td>5</td>
<td>L-thyroxine 75 µg 1×d/d</td>
<td>Not resolved</td>
<td>PR</td>
<td>f</td>
<td>53</td>
<td>No prior treatment</td>
</tr>
<tr>
<td>Hyperthyroidism</td>
<td>2</td>
<td>n</td>
<td>11</td>
<td>Prednisolone 40 mg p.o. 1×d, tapering 4 weeks; pause of nivolumab</td>
<td>Hyperthyroidism: resolved; destructive thyropathy: not resolved</td>
<td>PR</td>
<td>m</td>
<td>66</td>
<td>No prior treatment</td>
</tr>
<tr>
<td>Hyperthyroidism</td>
<td>1</td>
<td>p</td>
<td>3</td>
<td>No treatment</td>
<td>Resolved</td>
<td>SD</td>
<td>f</td>
<td>61</td>
<td>Dacarbazine; ipilimumab; carboplatin/paclitaxel; fotemustine</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>2</td>
<td>p</td>
<td>9</td>
<td>L-thyroxine 50 µg 1×d/d</td>
<td>Not resolved</td>
<td>SD</td>
<td>f</td>
<td>61</td>
<td>Dacarbazine; ipilimumab; carboplatin/paclitaxel; fotemustine</td>
</tr>
<tr>
<td>Hashimoto’s thyroiditis, hypothyroidism</td>
<td>2</td>
<td>p</td>
<td>18</td>
<td>L-thyroxine 75 µg 1×d/d</td>
<td>Not resolved</td>
<td>PR</td>
<td>m</td>
<td>46</td>
<td>Binimetinib; dacarbazine; anti-endosialin-antibody; ipilimumab</td>
</tr>
<tr>
<td>Hypocortisolism</td>
<td>2</td>
<td>p</td>
<td>18</td>
<td>Hydrocortisone 15 mg/d p.o.</td>
<td>Not resolved</td>
<td>PR</td>
<td>m</td>
<td>46</td>
<td>Polychemotherapy with litalir; dacarbazine; carmustine</td>
</tr>
<tr>
<td>Pituitary gland: thyreotropic insufficiency</td>
<td>2</td>
<td>p</td>
<td>10</td>
<td>Dose escalation L-thyroxine 75 µg 1×d/d</td>
<td>Not resolved</td>
<td>PR</td>
<td>f</td>
<td>71</td>
<td>Interferon-alpha; vemurafenib/ cobimetinib; ipilimumab; radiotherapy</td>
</tr>
<tr>
<td>Hyperthyroidism</td>
<td>2</td>
<td>p</td>
<td>11</td>
<td>Stop of base medication L-thyroxine</td>
<td>Resolved</td>
<td>PD</td>
<td>f</td>
<td>54</td>
<td>Interferon-alpha; dabrafenib; ipilimumab; vemurafenib; radiotherapy</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>1</td>
<td>p</td>
<td>7</td>
<td>No treatment</td>
<td>Not resolved</td>
<td>PD</td>
<td>f</td>
<td>44</td>
<td>Endosialin-antibody</td>
</tr>
<tr>
<td>Hypophysitis with secondary adrenal insufficiency</td>
<td>4</td>
<td>p</td>
<td>20</td>
<td>Dexamethasone 4 mg 4×d/d</td>
<td>Resolved</td>
<td>PD</td>
<td>m</td>
<td>79</td>
<td>No prior treatment</td>
</tr>
<tr>
<td>Hypothyroidism (worsening)</td>
<td>1</td>
<td>p</td>
<td>56</td>
<td>L-thyroxine</td>
<td>Not resolved</td>
<td>CR</td>
<td>f</td>
<td>63</td>
<td>Dacarbazine; ipilimumab</td>
</tr>
<tr>
<td>Thyroiditis</td>
<td>1</td>
<td>n</td>
<td>12</td>
<td>L-thyroxine</td>
<td>Not resolved</td>
<td>SD</td>
<td>f</td>
<td>54</td>
<td>Dabrafenib; ipilimumab</td>
</tr>
<tr>
<td>Thyroiditis</td>
<td>3</td>
<td>p</td>
<td>5</td>
<td>Initial: thiamazole (hyperthyroidism), following: L-thyroxine (hypothyroidism)</td>
<td>Not resolved</td>
<td>MR</td>
<td>m</td>
<td>83</td>
<td>Etoposide</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>2</td>
<td>p</td>
<td>8</td>
<td>L-thyroxine 50 µg/d</td>
<td>Not resolved</td>
<td>SD</td>
<td>f</td>
<td>65</td>
<td>Ipilimumab; dacarbazine; SIRT; plicaxel; radiotherapy</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>2</td>
<td>p</td>
<td>13</td>
<td>L-thyroxine 50 µg/d</td>
<td>Not resolved</td>
<td>PR</td>
<td>m</td>
<td>78</td>
<td>Dacarbazine; ipilimumab; paclitaxel</td>
</tr>
<tr>
<td>Thyroiditis</td>
<td>2</td>
<td>p</td>
<td>3</td>
<td>Thyroid replacement</td>
<td>Not resolved</td>
<td>PD</td>
<td>m</td>
<td>72</td>
<td>Dabrafenib/trametinib; ipilimumab; carboplatin/paclitaxel</td>
</tr>
<tr>
<td>Hyperthyroidism</td>
<td>2</td>
<td>n</td>
<td>7</td>
<td>Carbimazole p.o.</td>
<td>Resolved</td>
<td>PD</td>
<td>f</td>
<td>64</td>
<td>Radiotherapy; SIRT</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>2</td>
<td>p</td>
<td>6</td>
<td>No treatment</td>
<td>Not resolved</td>
<td>PR</td>
<td>f</td>
<td>48</td>
<td>Ipilimumab</td>
</tr>
<tr>
<td>Hyperthyroidism</td>
<td>1</td>
<td>p</td>
<td>15</td>
<td>No treatment</td>
<td>Resolved</td>
<td>PR</td>
<td>m</td>
<td>35</td>
<td>Ipilimumab</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>1</td>
<td>p</td>
<td>6</td>
<td>No treatment</td>
<td>Not resolved</td>
<td>PR</td>
<td>m</td>
<td>80</td>
<td>Dacarbazine; ipilimumab</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>2</td>
<td>p</td>
<td>10</td>
<td>L-thyroxine</td>
<td>Resolved</td>
<td>SD</td>
<td>f</td>
<td>63</td>
<td>Dacarbazine; ipilimumab</td>
</tr>
</tbody>
</table>

(continued on next page)
<table>
<thead>
<tr>
<th>Type of side-effect</th>
<th>Grade</th>
<th>Anti-PD-1 antibody</th>
<th>Occurrence in week(s) after initiation of anti-PD-1</th>
<th>Treatment of side-effect</th>
<th>Outcome of side-effect</th>
<th>Clinical tumour response to anti-PD-1</th>
<th>Gender (female/male)</th>
<th>Age</th>
<th>Pre-treatments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperthyroidism with thyroiditis</td>
<td>1</td>
<td>p</td>
<td>3</td>
<td>No treatment</td>
<td>Not resolved</td>
<td>PR</td>
<td>f</td>
<td>81</td>
<td>Dacarbazine; ipilimumab</td>
</tr>
<tr>
<td>Hyperthyroidism</td>
<td>2</td>
<td>p</td>
<td>4</td>
<td>Carbimazole</td>
<td>Not resolved</td>
<td>SD</td>
<td>m</td>
<td>60</td>
<td>Ipilimumab; dacarbazine</td>
</tr>
<tr>
<td>Diabetes mellitus type 3</td>
<td>3</td>
<td>n</td>
<td>6</td>
<td>Insulin therapy</td>
<td>Not resolved</td>
<td>CR</td>
<td>f</td>
<td>70</td>
<td>No prior treatment</td>
</tr>
<tr>
<td>Diabetes mellitus type 3</td>
<td>3</td>
<td>n</td>
<td>3</td>
<td>Insulin therapy</td>
<td>Not resolved</td>
<td>SD</td>
<td>f</td>
<td>78</td>
<td>Dacarbazine; ipilimumab; radiotherapy</td>
</tr>
<tr>
<td>Pituitary gland: insufficiency of the anterior lobe</td>
<td>3</td>
<td>n</td>
<td>5</td>
<td>Hydrocortisone p.o.</td>
<td>Not resolved</td>
<td>PD</td>
<td>m</td>
<td>44</td>
<td>Ipilimumab</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>1</td>
<td>n</td>
<td>2</td>
<td>Methylprednisolone 2 mg/kg/d; stop of nivolumab</td>
<td>Not resolved</td>
<td>PR</td>
<td>m</td>
<td>76</td>
<td>Ipilimumab; radiotherapy</td>
</tr>
<tr>
<td>Hypophysitis, hypopituitarism</td>
<td>2</td>
<td>n</td>
<td>2</td>
<td>Hydrocortisone p.o.</td>
<td>Not resolved</td>
<td>PD</td>
<td>f</td>
<td>60</td>
<td>Ipilimumab; radiotherapy</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>1</td>
<td>n</td>
<td>5</td>
<td>Beta-blocker</td>
<td>Not resolved</td>
<td>PD</td>
<td>f</td>
<td>60</td>
<td>Ipilimumab; radiotherapy</td>
</tr>
<tr>
<td>Hypophysitis, hypopituitarism</td>
<td>3</td>
<td>n</td>
<td>5</td>
<td>Pause of nivolumab; prednisolone initial 50 mg/d</td>
<td>Not resolved</td>
<td>SD</td>
<td>f</td>
<td>72</td>
<td>Interleukin-2 intratumoural; imatinib; ipilimumab; radiotherapy; thermoablato liver; electrochemotherapy with bleomycin</td>
</tr>
<tr>
<td>Diabetes mellitus type 3</td>
<td>3</td>
<td>p</td>
<td>3</td>
<td>Insulin therapy</td>
<td>Not resolved</td>
<td>SD</td>
<td>f</td>
<td>58</td>
<td>Ipilimumab; radiotherapy</td>
</tr>
<tr>
<td>Hypophysitis</td>
<td>2</td>
<td>i/p</td>
<td>17</td>
<td>Systemic hydrocortisone and thyroxine p.o.</td>
<td>Improved</td>
<td>SD</td>
<td>m</td>
<td>52</td>
<td>Radiotherapy</td>
</tr>
</tbody>
</table>

Abbreviations: p, pembrolizumab; n, nivolumab; i/p, ipilimumab/pembrolizumab; CTCAE, Common Terminology Criteria for Adverse Events; SD, stable disease; PR, partial response; PD, progressive disease; CR, complete response; MR, mixed response; SIRT, selective internal radiation therapy; MEK, mitogen-activated protein kinase; p.o., oral; s.c., subcutaneous.
be informed and remain aware of the side-effect profile of these immunotherapies. Quite often irAEs start quite subtle with minimal symptoms. If symptoms are autoimmune related, prompt treatment including high-dose corticosteroids can be necessary. Treatment with anti-PD-1 antibodies only has to be paused when AEs are severe and can often be resumed as documented in our study. If AEs are life threatening, anti-PD-1 treatment has to be discontinued.

Conflict of interest statement

Andrea Forschner is on the advisory board or/and has received honoraria from Merck Sharp & Dohme, Bristol-Meyers Squibb, Roche, and Novartis and travel support from MSD, Roche, and Novartis. Carmen Loquai is on the advisory board or/and has received honoraria or/and travel support from Roche, BMS, Merck, and Novartis. Simone Goldinger has received travel support from BMS, MSD, Roche, and Novartis and grants from University of Zurich. Lisa Zimmer is on the advisory board and/or has received honoraria from Roche, Bristol-Meyers Squibb, MSD, GSK, Novartis, and Merck and travel support from MSD, BMS, and Novartis. Selma Ugurel has received grants and travel support from Medac, personal fees from Roche and MSD, and travel support from BMS. Ralf Gutzmer has received personal fees from BMS, MSD, Merck, Roche, Novartis, GlaxoSmithKline, Pfizer, Amgen, Almirall-Hermal, LEO, Galderma, Janssen, Boehringer Ingelheim, grants from Novartis, Pfizer, Johnson & Johnson, and non-financial support from BMS, Novartis, GSK, and Amgen. Jochen Utikal has received financial support for performing clinical trials with PD-1 inhibitors from MSD and BMS and is on the advisory board from Roche, Novartis, GSK, and MSD; Daniela Göppner has received personal fees from Roche, BMS, Amgen, and MSD and non-financial support from Roche, Novartis, and Amgen. Jessica Hassel has received scientific support (investigator initiated trial) from BMS and is on the advisory board or/and has received honoraria from BMS, MSD, Roche, GSK, Novartis, and Amgen. Julia Tietze has received honoraria from Roche, MSD, BMS, and Novartis. Ioannis Thomas has received travel support from Roche. Carsten Weihaupt has received honoraria from BMS and MSD. Claus Garbe is on the advisory board or/and has received honoraria from Amgen, BMS, MSD, Novartis, Roche, and LEO and grants from BMS, Novartis and Roche. Thomas Eigenthaler is on the advisory board from BMS and has received travel support from MSD; Carola Berking is on the advisory board and/or has received honoraria from BMS, MSD, GSK, Novartis, Roche, Merck, Amgen, and AstraZeneca. Anja Gesierich has received travel support from BMS and MSD. Angola Krackhardt has received personal fees and grants from BMS. Dirk Schadendorf has received personal fees and patients’ fees from Roche, Novartis, GSK, Merck, and BMS and personal fees from Amgen, Boehringer Ingelheim, and LEO. Reinhard Dummer is on the advisory board and has received honoraria from Roche, BMS, MSD, GSK, Novartis, and Amgen and research funding from Roche, BMS, GSK, MSD, and Novartis. Lucie Heinzler has received honoraria from BMS and MSD, travel support from BMS, and financial support for performing clinical trials from MSD and BMS. All other authors have nothing to declare.

Funding

No additional funding was available for this study.

Acknowledgements

The authors would like to thank G. Metzler, Tübingen, and S. Schliep, Erlangen, for histopathologic diagnosis and reporting. The authors thank T. Bley,
Würzburg, for kindly providing a radiologic image. C. Bender, Heidelberg, has kindly supported patient documentation. The present work was performed in fulfillment of the requirements for obtaining the degree ‘Dr. med’.

References


